Praxis Precision Medicines (NASDAQ:PRAX) Price Target Raised to $73.00

Praxis Precision Medicines (NASDAQ:PRAX) had its price objective upped by Wedbush from $33.00 to $73.00 in a report published on Monday morning,Benzinga reports. They currently have an underperform rating on the stock. Wedbush also issued estimates for Praxis Precision Medicines’ Q3 2025 earnings at ($3.27) EPS, Q4 2025 earnings at ($3.27) EPS, FY2025 earnings at ($13.14) EPS, Q1 2026 earnings at ($3.10) EPS, Q2 2026 earnings at ($3.21) EPS, Q3 2026 earnings at ($3.45) EPS, Q4 2026 earnings at ($3.60) EPS, FY2026 earnings at ($13.36) EPS, FY2027 earnings at ($14.43) EPS, FY2028 earnings at ($10.41) EPS and FY2029 earnings at ($5.15) EPS.

A number of other research firms also recently issued reports on PRAX. Jefferies Financial Group reissued a “buy” rating and issued a $300.00 price target (up from $65.00) on shares of Praxis Precision Medicines in a research note on Thursday, October 16th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $280.00 price objective (up previously from $65.00) on shares of Praxis Precision Medicines in a report on Friday, October 17th. Truist Financial restated a “buy” rating and issued a $360.00 price objective (up previously from $85.00) on shares of Praxis Precision Medicines in a report on Friday, October 17th. HC Wainwright lifted their price objective on shares of Praxis Precision Medicines from $115.00 to $232.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Praxis Precision Medicines in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Praxis Precision Medicines presently has a consensus rating of “Moderate Buy” and a consensus target price of $222.36.

Praxis Precision Medicines Stock Performance

Praxis Precision Medicines stock opened at $184.43 on Monday. The company’s 50 day simple moving average is $60.95 and its 200-day simple moving average is $48.86. The company has a market capitalization of $3.90 billion, a price-to-earnings ratio of -15.01 and a beta of 2.62. Praxis Precision Medicines has a 1 year low of $26.70 and a 1 year high of $205.89.

Praxis Precision Medicines (NASDAQ:PRAX) last released its quarterly earnings results on Monday, August 4th. The company reported ($3.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.09. Equities analysts expect that Praxis Precision Medicines will post -10.22 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its holdings in Praxis Precision Medicines by 88.3% during the 2nd quarter. Nisa Investment Advisors LLC now owns 629 shares of the company’s stock worth $26,000 after acquiring an additional 295 shares in the last quarter. CWM LLC grew its holdings in Praxis Precision Medicines by 877.9% during the 2nd quarter. CWM LLC now owns 753 shares of the company’s stock worth $32,000 after acquiring an additional 676 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Praxis Precision Medicines by 24.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company’s stock worth $77,000 after acquiring an additional 359 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in Praxis Precision Medicines during the 3rd quarter worth approximately $207,000. Finally, GAMMA Investing LLC grew its holdings in Praxis Precision Medicines by 6,075.4% during the 1st quarter. GAMMA Investing LLC now owns 4,014 shares of the company’s stock worth $152,000 after acquiring an additional 3,949 shares in the last quarter. Institutional investors and hedge funds own 67.84% of the company’s stock.

About Praxis Precision Medicines

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.